EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy

Astrid L Voskamp iD, Sugandhika Khosa, Tracy Phan iD, Hannah A DeBerg iD, Judy Bingham, Mark Hew iD, William Smith iD, Jodie Abramovitch iD, Jennifer M Rolland iD, Matthew Moyle, Kari C Nadeau iD, Gideon Lack iD und 5 weitere

Allergy · 2024

DOI: 10.1111/all.15966 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2024. Verfasst von Astrid L Voskamp und 16 weiteren Autor:innen. Beteiligte Einrichtung: Aravax Pty Ltd, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Anaphylaxis. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Alfred Research Trusts, Alfred Health, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Food allergy is a leading cause of anaphylaxis worldwide. Allergen‐specific immunotherapy is the only treatment shown to modify the natural history of allergic disease, but application to food allergy has been hindered by risk of severe allergic reactions and short‐lived efficacy. Allergen‐derived peptides could provide a solution. PVX108 comprises seven short peptides representing immunodominant T‐cell epitopes of major peanut allergens for treatment of peanut allergy.

Methods

Pre‐clinical safety of PVX108 was assessed using ex vivo basophil activation tests ( n = 185). Clinical safety and tolerability of single and repeat PVX108 doses were evaluated in a first‐in‐human, randomized, double‐blind, placebo‐controlled trial in peanut‐allergic adults (46 active, 21 placebo). The repeat‐dose cohort received six doses over 16 weeks with safety monitored to 21 weeks. Exploratory immunological analyses were performed at pre‐dose, Week 21 and Month 18 after treatment.

Results

PVX108 induced negligible activation of peanut‐sensitised basophils. PVX108 was safe and well tolerated in peanut‐allergic adults. There were no treatment‐related hypersensitivity events or AEs of clinical concern. The only events occurring more frequently in active than placebo were mild injection site reactions. Exploratory immunological analyses revealed a decrease in the ratio of ST2 + Th2A:CCR6 + Th17‐like cells within the peanut‐reactive Th pool which strengthened following treatment.

Conclusion

This study supports the concept that PVX108 could provide a safe alternative to whole peanut immunotherapies and provides evidence of durable peanut‐specific T‐cell modulation. Translation of these findings to clinical efficacy in ongoing Phase 2 trials would provide important proof‐of‐concept for using peptides to treat food allergy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peanut HypersensitivityAnaphylaxisAdultHumansDesensitization, ImmunologicBasophilsArachisAllergensAdministration, Oral

Stichwörter der Autor:innen

T cellfood allergypeptide immunotherapyphase 1 clinical trial

Substanzen

Allergens

Autor:innen und Institutionen

  • Aravax Pty Ltd, Melbourne, Victoria, Australia.
  • Monash University, Melbourne, Victoria, Australia.
  • Alfred Health, Melbourne, Victoria, Australia.
  • WhiteFox Science Consulting, Nelson, New Zealand.
  • Benaroya Research Institute, Seattle, Washington, USA.
  • Easington Pty Ltd, Melbourne, Victoria, Australia.

ORCID-Profile: Astrid L Voskamp, Tracy Phan, Hannah A DeBerg, Mark Hew, William Smith, Jodie Abramovitch, Jennifer M Rolland, Kari C Nadeau, Gideon Lack, Mark Larché, Erik Wambre, Robyn E O'Hehir, Pascal Hickey, Sara R Prickett

Förderung

  • NIH HHS
  • Alfred Research Trusts, Alfred Health
  • National Health and Medical Research Council
  • National Institutes of Health

Zitieren

APA

Voskamp, A. L., Khosa, S., Phan, T., DeBerg, H. A., Bingham, J., Hew, M., Smith, W., Abramovitch, J., Rolland, J. M., Moyle, M., Nadeau, K. C., Lack, G., Larché, M., Wambre, E., O'Hehir, R. E., Hickey, P., & Prickett, S. R. (2024). Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy. Allergy. https://doi.org/10.1111/all.15966

Vancouver

Voskamp AL, Khosa S, Phan T, DeBerg HA, Bingham J, Hew M, et al. Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy. Allergy. 2024. doi:10.1111/all.15966

BibTeX
@article{Voskamp2024,
  author = {Voskamp, Astrid L and Khosa, Sugandhika and Phan, Tracy and DeBerg, Hannah A and Bingham, Judy and Hew, Mark and Smith, William and Abramovitch, Jodie and Rolland, Jennifer M and Moyle, Matthew and Nadeau, Kari C and Lack, Gideon and Larché, Mark and Wambre, Erik and O'Hehir, Robyn E and Hickey, Pascal and Prickett, Sara R},
  title = {Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.15966}
}
Kostenlos starten →